|
A more recent version of this article appeared on July 1, 2003
Papers In Press, published online ahead of print March 16, 2003
J. Lipid Res., doi:10.1194/jlr.R200018-JLR200
Submitted on November 19, 2002
Revised on March 6, 2003
Accepted on March 10, 2003
Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease
S. Matthijs Boekholdt and John F. Thompson
Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton, CT 06340
Corresponding Author: john_f_thompson{at}groton.pfizer.com
Since the identification of CETP, its role in the modulation of HDL levels and cardiovascular disease has been debated. With the early detection of genetic variants followed by the finding of families deficient in CETP, genetic studies have played a large role in the attempts to understand the association of CETP with lipids and disease. However, results of these studies have often led to disparate conclusions. With the availability of a greater variety of genetic polymorphisms and larger studies in which disease has been examined, it is now possible to compare the breadth of CETP genetic studies and draw better conclusions. The most broadly studied polymorphism is TaqIB for which over 10,000 individuals have been genotyped and HDL levels determined. When these studies are subjected to a meta-analysis, the B2B2 homozygotes are found to have higher HDL levels than B1B1 homozygotes (0.12 mmol/l, 95% CI = 0.11-0.13, p<0.0001). A similar analysis of the I405V polymorphism yields 0.05 mmol/l higher HDL levels in 405VV homozygotes than in 405II homozygotes (95% CI = 0.03-0.07, p<0.0001). The implications of these studies for cardiovascular disease will be addressed.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. P F Dullaart, G. van den Berg, A. M van der Knaap, J. Dijck-Brouwer, G. M Dallinga-Thie, P. M J Zelissen, W. J Sluiter, and A. P van Beek
HDL cholesterol response to GH replacement is associated with common cholesteryl ester transfer protein gene variation (-629C>A) and modified by glucocorticoid treatment
Eur. J. Endocrinol.,
February 1, 2010;
162(2):
227 - 234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Sofat, A. D. Hingorani, L. Smeeth, S. E. Humphries, P. J. Talmud, J. Cooper, T. Shah, M. S. Sandhu, S. L. Ricketts, S. M. Boekholdt, et al.
Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms
Circulation,
January 5, 2010;
121(1):
52 - 62.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Vasan, M. J. Pencina, S. J. Robins, J. P. Zachariah, G. Kaur, R. B. D'Agostino, and J. M. Ordovas
Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community
Circulation,
December 15, 2009;
120(24):
2414 - 2420.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Lira, A. K. Loomis, S. A. Paciga, D. B. Lloyd, and J. F. Thompson
Expression of CETP and of splice variants induces the same level of ER stress despite secretion efficiency differences
J. Lipid Res.,
September 1, 2008;
49(9):
1955 - 1962.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Thompson, E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R. P. F. Dullaart, B. Keavney, Z. Ye, and J. Danesh
Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk
JAMA,
June 18, 2008;
299(23):
2777 - 2788.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. J. Lackner, L. J. Cohn, R. P. Dullaart, A. C. M. Kobold, A. van Tol, P. Barter, C. L. Shear, J. H. Revkin, and D. J. Rader
Torcetrapib and Coronary Events
N. Engl. J. Med.,
April 24, 2008;
358(17):
1862 - 1864.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Spielmann, A. S. Leon, D. C. Rao, T. Rice, J. S. Skinner, C. Bouchard, and T. Rankinen
CETP genotypes and HDL-cholesterol phenotypes in the HERITAGE Family Study
Physiol Genomics,
September 11, 2007;
31(1):
25 - 31.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Isaacs, Y. S. Aulchenko, A. Hofman, E. J. G. Sijbrands, F. A. Sayed-Tabatabaei, O. H. Klungel, A.-H. Maitland-van der Zee, B. H. Ch. Stricker, B. A. Oostra, J. C. M. Witteman, et al.
Epistatic Effect of Cholesteryl Ester Transfer Protein and Hepatic Lipase on Serum High-Density Lipoprotein Cholesterol Levels
J. Clin. Endocrinol. Metab.,
July 1, 2007;
92(7):
2680 - 2687.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Thompson, L. S. Wood, E. H. Pickering, B. DeChairo, and C. L. Hyde
High-density genotyping and functional SNP localization in the CETP gene
J. Lipid Res.,
February 1, 2007;
48(2):
434 - 443.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. K. Shah
Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease
Eur. Heart J.,
January 1, 2007;
28(1):
5 - 12.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Borggreve, H. L. Hillege, B. H. R. Wolffenbuttel, P. E. de Jong, M. W. Zuurman, G. van der Steege, A. van Tol, R. P. F. Dullaart, and on behalf of the PREVEND Study Group
An Increased Coronary Risk Is Paradoxically Associated with Common Cholesteryl Ester Transfer Protein Gene Variations That Relate to Higher High-Density Lipoprotein Cholesterol: A Population-Based Study
J. Clin. Endocrinol. Metab.,
September 1, 2006;
91(9):
3382 - 3388.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L.E. Klos, C. F. Sing, E. Boerwinkle, S. C. Hamon, T. J. Rea, A. Clark, M. Fornage, and J. E. Hixson
Consistent Effects of Genes Involved in Reverse Cholesterol Transport on Plasma Lipid and Apolipoprotein Levels in CARDIA Participants
Arterioscler Thromb Vasc Biol,
August 1, 2006;
26(8):
1828 - 1836.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H.E.M. Klerkx, K. E. Harchaoui, W. A. van der Steeg, S. M. Boekholdt, E. S.G. Stroes, J. J.P. Kastelein, and J. A. Kuivenhoven
Cholesteryl Ester Transfer Protein (CETP) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels: Pathways by Which Modulation of CETP Activity May Alter Atherogenesis
Arterioscler Thromb Vasc Biol,
April 1, 2006;
26(4):
706 - 715.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Barter and J. J.P. Kastelein
Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease
J. Am. Coll. Cardiol.,
February 7, 2006;
47(3):
492 - 499.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Deguchi, N. M. Pecheniuk, D. J. Elias, P. M. Averell, and J. H. Griffin
High-Density Lipoprotein Deficiency and Dyslipoproteinemia Associated With Venous Thrombosis in Men
Circulation,
August 9, 2005;
112(6):
893 - 899.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Borggreve, H. L. Hillege, B. H. R. Wolffenbuttel, P. E. de Jong, S. J. L. Bakker, G. van der Steege, A. van Tol, R. P. F. Dullaart, and on behalf of the PREVEND Study Group
The Effect of Cholesteryl Ester Transfer Protein -629C->A Promoter Polymorphism on High-Density Lipoprotein Cholesterol Is Dependent on Serum Triglycerides
J. Clin. Endocrinol. Metab.,
July 1, 2005;
90(7):
4198 - 4204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. B. Lloyd, M. E. Lira, L. S. Wood, L. K. Durham, T. B. Freeman, G. M. Preston, X. Qiu, E. Sugarman, P. Bonnette, A. Lanzetti, et al.
Cholesteryl Ester Transfer Protein Variants Have Differential Stability but Uniform Inhibition by Torcetrapib
J. Biol. Chem.,
April 15, 2005;
280(15):
14918 - 14922.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. J. de Grooth, A. H. E. M. Klerkx, E. S. G. Stroes, A. F. H. Stalenhoef, J. J. P. Kastelein, and J. A. Kuivenhoven
A review of CETP and its relation to atherosclerosis
J. Lipid Res.,
November 1, 2004;
45(11):
1967 - 1974.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Wolfe and D. J. Rader
Cholesteryl Ester Transfer Protein and Coronary Artery Disease: An Observation With Therapeutic Implications
Circulation,
September 14, 2004;
110(11):
1338 - 1340.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Boekholdt, J.-A. Kuivenhoven, N. J. Wareham, R. J.G. Peters, J. W. Jukema, R. Luben, S. A. Bingham, N. E. Day, J. J.P. Kastelein, and K.-T. Khaw
Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The Prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk Population Study
Circulation,
September 14, 2004;
110(11):
1418 - 1423.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Barzilai, G. Atzmon, C. Schechter, E. J. Schaefer, A. L. Cupples, R. Lipton, S. Cheng, and A. R. Shuldiner
Unique Lipoprotein Phenotype and Genotype Associated With Exceptional Longevity
JAMA,
October 15, 2003;
290(15):
2030 - 2040.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|